

Special Issue

microRNAs in Health and Disease

Message from the Guest Editors

microRNAs (miRNAs) are small non-coding RNAs and key gene expression regulators at the post-transcriptional level. miRNA-dependent gene expression regulation is fundamental in almost all biological processes. As a consequence, its dysregulation plays a relevant role in the onset and progression of several diseases. Consistently, knowledge of the complex regulatory networks established by miRNAs together with mRNAs and the different non-coding RNAs classes (e.g., linear long non-coding RNAs and circular RNAs) may represent a huge source of therapeutic targets. The aim of this Special Issue is to collect original research papers, reviews and commentaries focused on the recent advances in the field of miRNAs in both health and disease. Of special interest are new insights into miRNAs mechanisms of action underlying physiological and pathological processes and diseases, miRNA-associated therapeutic target discovery, miRNA-associated RNA-based therapy (including miRNAs delivery systems), miRNA biomarkers (including circulating miRNAs) and miRNAs in cell-to-cell communication.

Guest Editors

Dr. Milena Rizzo

Institute of Clinical Physiology (IFC), National Research Council (CNR),
Via Moruzzi 1, 56124 Pisa, Italy

Dr. Elena Levantini

Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche,
via Moruzzi 1, 56124 Pisa, Italy

Deadline for manuscript submissions

closed (15 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/110639

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).